Savings are vs. buying the same number of pouches at $64.95 each, the single-pouch price from Dec 1, 2026. 30% applies only to the first 8-pouch subscription shipment ($363.72 vs. 8 × $64.95); other options save 13%–25%. Later shipments renew at the regular subscription price.
Ends Mon Nov 30, 11:59 PM ET (8:59 PM PT).
HealthspanX / Publication archive
Explore individual publications and their study records. Read the source, the findings and the limits together.
Human randomized trial / 2023
80-person dose-ranging RCT: 300–900 mg/day NMN raised blood NAD over 60 days; secondary functional findings were positive while HOMA-IR was null.
GeroScience
Read study recordHuman randomized trial / 2023
24-week placebo-controlled study in 14 older men with diabetes found NMN tolerable but no significant benefit for grip strength or walking speed.
Geriatrics & Gerontology International
Read study recordEarly human intervention / 2022
Single-arm study in 17 postmenopausal women found multiple biomarker changes over 8 weeks; without a control group, causal effects cannot be established.
Glycative Stress Research
Read study recordHuman randomized trial / 2022
60-day RCT of 300 mg/day NMN reported higher NAD+/NADH and some secondary benefits, but post-unblinding participant selection limits interpretation.
Frontiers in Aging
Read study recordHuman randomized trial / 2022
Older-men RCT: 250 mg/day NMN increased blood NAD-related metabolites; nominal gait/grip findings were limited by a test-food allocation error.
npj Aging
Read study recordHuman randomized trial / 2022
Four-week RCT in 31 healthy adults found 1,250 mg/day NMN was well tolerated without severe adverse events or clinically concerning laboratory changes.
Scientific Reports
Read study recordHuman randomized trial / 2022
In 30 healthy Japanese adults, 250 mg/day NMN for 12 weeks increased whole-blood NAD+ without serious adverse events; clinical metabolic and body-composition outcomes did not significantly change.
Frontiers in Nutrition
Read study recordPreclinical mechanistic study / 2022
High-dose injected NMN improved albuminuria and several renal measures in a mouse injury model; no human intervention was performed.
Scientific Reports
Read study recordPreclinical mechanistic study / 2023
Injected NMN reduced injury markers and improved later behavior in neonatal mice after experimental hypoxia–ischemia; no human outcomes were studied.
ASN Neuro
Read study recordNarrative review / 2024
A broad review describes extensive preclinical research but finds human evidence small, short, inconsistent, and insufficient for broad clinical claims.
Frontiers in Pharmacology
Read study recordNarrative review / 2023
A narrative review found generally reassuring short-term tolerability but scarce, inconsistent evidence for broad anti-aging effects in humans.
Advances in Nutrition
Read study recordHuman randomized trial / 2026
In a 14-day randomized trial, 1 g/day NMN and NR roughly doubled whole-blood NAD+, while nicotinamide did not; clinical outcomes were not tested.
Nature Metabolism
Read study recordThe Evidence Center brings study design, findings and limitations into the same view.
